Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • Revenue in USD (TTM)52.55bn
  • Net income in USD10.60bn
  • Incorporated1942
  • Employees90.20k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttp://www.pfizer.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Abbott Laboratories27.39bn1.81bn108.73bn99.00k59.963.5122.493.971.040.274215.7017.720.42494.096.45276,666.702.813.683.214.5454.9855.356.628.471.862.730.473179.6831.357.5370.5650.22-8.76-12.01
Amgen, Inc.22.85bn8.08bn131.54bn20.80k16.605.2213.115.7611.002.5931.1234.950.291.467.141,098,510.0010.259.3911.7610.7182.1980.9635.3631.045.1726.520.583438.42-0.61765.764.6213.21-0.736526.15
Merck & Co., Inc.40.12bn5.00bn147.29bn69.00k30.024.2915.263.671.820.86214.6412.730.43792.535.78581,478.305.486.006.837.4268.6565.1512.5114.521.0620.210.413986.640.7913-3.2227.40-4.13-0.68492.28
AbbVie Inc28.22bn8.88bn177.90bn29.00k20.2234.9917.056.305.543.3017.603.200.41234.545.73972,965.5013.0211.5316.1314.8875.4777.2731.5722.441.186.750.8865.1510.068.9549.9710.999.70--
Pfizer Inc.52.55bn10.60bn216.27bn90.20k20.753.0512.784.121.753.528.6711.930.3061.516.39582,549.906.205.297.586.3079.3179.9020.2817.771.1015.890.377778.68-0.5263-0.784747.353.369.337.78
Data as of Mar 20 2018. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

25.01%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2017423.73m7.12%
SSgA Funds Management, Inc.as of 31 Dec 2017309.98m5.21%
BlackRock Fund Advisorsas of 31 Dec 2017280.35m4.71%
Northern Trust Investments, Inc.as of 31 Dec 201779.76m1.34%
JPMorgan Investment Management, Inc.as of 31 Dec 201779.72m1.34%
Wellington Management Co. LLPas of 31 Dec 201769.29m1.16%
Geode Capital Management LLCas of 31 Dec 201763.12m1.06%
T. Rowe Price Associates, Inc.as of 31 Dec 201762.00m1.04%
Massachusetts Financial Services Co.as of 31 Dec 201760.83m1.02%
State Farm Investment Management Corp.as of 31 Dec 201759.68m1.00%
More ▼
Data from 31 Dec 2017 - 31 Dec 2017Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.